KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 2243 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Tertiary lymphoid structure-related RNA indicator as metastasis risk factor in nasopharyngeal carcinoma. PMID 41397929 · Clin Transl Med · 2025-Dec The record is eligible for oncology, human, randomized, Phase III, and time-to-event criteria. However, it is not eligible as a primary result report of a randomized drug trial. The study is a secondary/prognostic model analysis that uses a Phase III trial cohort for external validation. The abstract does not describe the drug intervention in the referenced trial or present its primary efficacy results. Therefore, it fails the 'drug_intervention' and 'original_result' (as a primary trial report) criteria for Kaplan-Meier digitization of a drug trial.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design. PMID 41388832 · Future Oncol · 2025-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer. PMID 41383151 · Future Oncol · 2025-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study. PMID 41318310 · Dig Liver Dis · 2025-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials. PMID 41270639 · Lung Cancer · 2025-Dec 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H S B
严格 v3 独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Early stoppage of empirical antibiotic therapy in paediatric acute leukaemia with high-risk febrile neutropenia: a randomized, open-label, phase 3, non-inferiority trial. PMID 41245542 · EClinicalMedicine · 2025-Dec The study is an eligible oncology RCT with drug intervention, but its primary efficacy endpoint is a binary proportion (fever recurrence), not a time-to-event endpoint. Therefore, it does not meet the specific requirement for Kaplan-Meier/HR-based efficacy analysis.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial. PMID 41245539 · EClinicalMedicine · 2025-Dec This is a methodological reanalysis of an existing Phase III trial, not the original trial report. The abstract does not specify the drug intervention used in the HOVON87/NMSG18 trial, only referencing it as a 'novel drug' trial. The primary focus is on evaluating adaptive trial designs, not reporting the original efficacy results of a specific drug regimen.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer. PMID 41197381 · Lung Cancer · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review. PMID 41192027 · Cancer Treat Rev · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis. PMID 41162296 · Dig Liver Dis · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Overlooked and underreported: A systematic review of quality of life in recent Phase III metastatic breast cancer trials. PMID 41130338 · J Cancer Policy · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial. PMID 41109921 · Nat Med · 2025-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 6 Panel · risk visible
Maintenance after first-line treatment for advanced soft tissue sarcoma. PMID 40975452 · Crit Rev Oncol Hematol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Quality of life results and survival outcomes in trials of immunotherapy in advanced cancers: A systematic review and meta-research study. PMID 40975451 · Crit Rev Oncol Hematol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Palbociclib treatment in patients with HR+/HER2- advanced or metastatic breast cancer and visceral metastasis: A systematic literature review. PMID 40945169 · Breast · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis. PMID 40288918 · Eur Urol Oncol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Platform study of circulating tumor DNA directed adjuvant chemotherapy in colon cancer (CLAUDIA colon cancer, KCSG CO22-12). PMID 40855542 · BMC Cancer · 2025-Aug-25 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials. PMID 40853558 · Ann Surg · 2025-Aug-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
SOTA: A statistical tool for quantifying the superiority onset time of PD-1/PD-L1 inhibitor response based on Kaplan-Meier graphics and its application in a meta-analysis of NSCLC randomized controlled trials. PMID 40851388 · Chin Med J (Engl) · 2025-Aug-25 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis. PMID 40901310 · World J Clin Oncol · 2025-Aug-24 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis. PMID 40826400 · BMC Cancer · 2025-Aug-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of PD-1 inhibitors in combination with chemotherapy as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction cancer across subgroups: A comprehensive systematic review and meta-analysis. PMID 40826733 · Medicine (Baltimore) · 2025-Aug-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Neoadjuvant Chemotherapy with or without Immune Checkpoint Inhibitors for Resectable Esophageal Squamous Cell Carcinoma: a Meta-analysis of Randomized Controlled Trials. PMID 40788432 · J Gastrointest Cancer · 2025-Aug-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Nivolumab plus ipilimumab: A promising first-line therapy for hepatocellular carcinoma. PMID 40782666 · Med · 2025-Aug-08 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Phase II single vs hypofractionated irradiation for timely access to partial breast radiotherapy (SHIFT-PB). PMID 40781619 · BMC Cancer · 2025-Aug-08 The record describes a Phase II randomized controlled trial protocol for a radiation therapy fractionation study, not a report of results from a Phase III/IIIb or definitive Phase II/III randomized trial with drug intervention and time-to-event efficacy endpoints.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis. PMID 40653807 · Oncologist · 2025-Aug-04 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
A randomized, placebo-controlled phase III trial of an autologous, formalin-fixed tumor vaccine for newly diagnosed glioblastoma: trial protocol. PMID 40377260 · Jpn J Clin Oncol · 2025-Aug-03 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect size estimation in cooperative group- and industry-sponsored phase 3 oncology trials. PMID 40220316 · J Natl Cancer Inst · 2025-Aug-01 This is a meta-analysis/review article that aggregates data from multiple trials. It is not an original report of a single randomized trial with a drug intervention and a time-to-event efficacy endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources. PMID 41551572 · Blood Neoplasia · 2025-Aug The report is a Phase III randomized trial with time-to-event endpoints, but the intervention (omidubicel, a cell therapy product) does not meet the 'drug intervention' criterion for this adjudication cohort.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radiation and Medical Oncology Perspectives on Oligometastatic Disease Treatment. PMID 41048473 · Fed Pract · 2025-Aug 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta-Epidemiological Analysis. PMID 40879280 · Cancer Med · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial. PMID 40831891 · Liver Cancer · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Evolving Landscape of Systemic Immunotherapy for Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer: At the Edge of a Tsunami? PMID 40752989 · Eur Urol Oncol · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Short-Term Results of the SONCAR Study: Optimized Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients. PMID 40703195 · MedComm (2020) · 2025-Aug 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients. PMID 40669094 · ESMO Open · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The use of machine learning models to predict progression-free survival and overall survival outcomes from waterfall plots in randomized clinical trials (MAP-OUTCOMES). PMID 40664145 · ESMO Open · 2025-Aug 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Nurse AMIE randomized controlled trial to address symptom management among rural advanced Cancer patients: Addressing malignancies in everyday life. PMID 40651555 · Contemp Clin Trials · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ADJUPANC protocol: a phase III study of adjuvant chemotherapy versus chemoradiotherapy for pancreatic cancer. PMID 40583350 · Future Oncol · 2025-Aug The record is a clinical trial protocol (NCT06427447) without reported results. It describes a planned Phase III randomized trial in pancreatic cancer with drug intervention (gemcitabine, capecitabine) and mentions survival outcomes as aims, but does not contain any reported Kaplan-Meier curves, hazard ratios, or other time-to-event efficacy results. Therefore, it is excluded as a protocol without results.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Current advances and challenges in minimally invasive esophagectomy. PMID 40536623 · Int J Clin Oncol · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all? PMID 40476645 · Tumori · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Stereotactic body radiotherapy for oligometastatic disease: current evidence and future perspectives. PMID 40382526 · Int J Clin Oncol · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of finotonlimab plus docetaxel vs. docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trial. PMID 40386729 · Transl Lung Cancer Res · 2025-Apr-30 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 4 Panel · risk visible
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. PMID 40284030 · Pharmaceuticals (Basel) · 2025-Apr-19 This is a real-world, non-randomized study (AENEID) evaluating IsaKd. While it reports time-to-event efficacy results (PFS, OS) for a drug regimen, it is not a randomized controlled trial and does not represent the original Phase III/IIIb trial results for the drug combination. The original Phase III trial (IKEMA) is referenced but is not the subject of this record.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review. PMID 40321256 · medRxiv · 2025-Apr-16 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Comparative efficacy and safety in low-intensity treatment for acute myeloid leukemia in older patients: a systematic review and network meta-analysis. PMID 40229815 · Eur J Med Res · 2025-Apr-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer. PMID 39729390 · Int J Cancer · 2025-Apr-15 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 1 Panel · risk visible
SMALL: open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer-protocol for a phase III randomised multicentre trial. PMID 40204306 · BMJ Open · 2025-Apr-08 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). PMID 40186126 · BMC Cancer · 2025-Apr-04 The publication is a clinical trial protocol for a Phase III randomized trial comparing a drug (177Lu-edotreotide) to another drug (everolimus) with a primary time-to-event efficacy endpoint (PFS). However, it does not contain results; it is a protocol description. Therefore, it is not an original formal-result report and is excluded.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The value of PFS36 as a primary endpoint for radiotherapy trials in patients with LACC: individual patient data from the Chinese NCC and validation from 26 RCTs. PMID 40265093 · J Natl Cancer Cent · 2025-Apr The record describes a methodological study validating a surrogate endpoint (PFS36 for OS) by analyzing aggregated data from multiple existing Phase III radiotherapy trials. It is not an original result report from a single randomized trial with a drug-containing intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic review. PMID 40175003 · Lancet Haematol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -